FactaeThe Factual News

Genfit to launch Phase 2 study on NTZ for ACLF on July 9, 2026

Genfit initiates a Phase 2 clinical trial on July 9, 2026.

Published 8sem1 sourceNotableupdated 1sem

Lire en français

≈ 17sSpeed

The fact

The study assesses nitazoxanide (NTZ) for treating acute-on-chronic liver failure (ACLF).

The announcement was reported by Boursorama.

Click the link to read an article on the topic:

Explore this topic

Genfit Boursorama #Apnimed #IPO #apnée du sommeil #biotech #médicament

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.

France · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →

Follow topic →

Auto-synthesis from 1 media source · identified on July 10, 2026

← Back to home

Discover

Read more

All marches →